These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 30173085)

  • 1. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
    Atkins MB; Tannir NM
    Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
    Flippot R; Escudier B; Albiges L
    Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy for renal cell carcinoma - current status].
    Grimm MO; Foller S
    Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
    Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
    Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma.
    Serzan MT; Atkins MB
    J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 35295921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
    Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
    J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
    Tannir NM; Pal SK; Atkins MB
    Oncologist; 2018 May; 23(5):540-555. PubMed ID: 29487224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapeutics in refractory renal cell carcinoma.
    Koshkin VS; Rini BI
    Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions.
    Merza H; Bilusic M
    Curr Oncol Rep; 2017 Apr; 19(4):27. PubMed ID: 28303494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
    Cetin B; Wabl CA; Gumusay O
    Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.
    Lambea J; Anido U; Etxániz O; Flores L; Montesa Á; Sepúlveda JM; Esteban E
    Curr Oncol Rep; 2016 Nov; 18(11):66. PubMed ID: 27613167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
    Zahoor H; Rini BI
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
    Loo V; Salgia M; Bergerot P; Philip EJ; Pal SK
    Target Oncol; 2019 Dec; 14(6):639-645. PubMed ID: 31595385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
    Gulati S; Vaishampayan U
    Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.